Your browser doesn't support javascript.
loading
Advances in remission induction therapy for ANCA-associated vasculitis.
Morris, Adam; Geetha, Duvuru.
Afiliação
  • Morris A; Renal Medicine, Royal Preston Hospital, Preston, UK.
  • Geetha D; Division of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. Electronic address: dgeetha1@jhmi.edu.
Best Pract Res Clin Rheumatol ; 37(1): 101828, 2023 03.
Article em En | MEDLINE | ID: mdl-37244804
ABSTRACT
Since its first description 40 years ago, huge strides have been made in the management of ANCA-associated vasculitis with improved patient outcomes. The use of cyclophosphamide and/or B-cell depleting therapy alongside glucocorticoids remains the cornerstone of therapy in organ or life-threatening disease, but recent trials have re-evaluated existing treatment strategies, alongside the development of new treatment targets. This has led to refinement of the role of plasma exchange, the use of reduced dosing of oral glucocorticoids with improved patient outcomes, as well as other treatment adjuvants/options of steroid minimization including C5a receptor antagonism and IL-5 inhibition. In this review we examine developments in remission induction therapy for ANCA-associated vasculitis.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos / Imunossupressores Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos / Imunossupressores Idioma: En Ano de publicação: 2023 Tipo de documento: Article